Welcome to our dedicated page for Labcorp Holdings SEC filings (Ticker: LH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Labcorp Holdings Inc. (NYSE: LH), a global provider of innovative and comprehensive laboratory services. These documents offer detailed information about the company’s operations, financial condition, governance and material events.
Labcorp’s recent current reports on Form 8-K include disclosures about quarterly and annual financial results, updated guidance and capital allocation decisions such as cash dividends on its common stock. Other 8-K filings describe participation in investor conferences, appointments and retirements of directors and executives, and transactions affecting parts of its business, such as the sale of select early development medical device testing assets.
Filings also confirm that Labcorp’s common stock, with a par value of $0.10 per share, is registered under Section 12(b) of the Securities Exchange Act and trades on the New York Stock Exchange under the symbol LH. Segment information released through earnings-related filings outlines performance for the Diagnostics Laboratories and Biopharma Laboratory Services segments, providing context on demand for clinical testing and biopharma laboratory services.
On Stock Titan, Labcorp’s SEC filings are updated as they become available from EDGAR. AI-powered summaries help explain the key points in complex documents, so readers can quickly understand items such as results of operations, changes in leadership, dividend declarations and significant transactions. Users can review Forms 8-K for material events, as well as other core filings like annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy materials when they are filed.
For investors, analysts and other interested readers, this page serves as a focused entry point into Labcorp’s regulatory disclosures, combining real-time updates with AI-generated highlights to make the information easier to interpret.
Labcorp Holdings Inc. director Kerrii B. Anderson received an equity award of 773 Restricted Stock Units on February 10, 2026. The award was reported as an acquisition of derivative securities at a price of $0 per unit under a standard grant or award transaction code.
Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. common stock. These units vest fully on February 10, 2027. Following this grant, Anderson beneficially owns a total of 1,670 Restricted Stock Units, all held as direct ownership.
A holder of Laboratory Corporation of America Holdings (LH) common stock has filed a Rule 144 notice to sell 87 shares through Fidelity Brokerage Services on the NYSE, with an approximate sale date of 02/12/2026 and an aggregate market value of $25,266.54.
The 87 shares were acquired on 02/11/2026 via restricted stock vesting from the issuer as compensation. In the past three months, Jonathan Meltzer sold LH common stock in two transactions: 88 shares on 02/09/2026 for $24,246.64 and 91 shares on 02/10/2026 for $25,187.89.
An insider has filed a Form 144 notice indicating an intention to sell up to 5,273 shares of common stock, with an aggregate market value of $1,499,535.74. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 02/11/2026.
The securities to be sold were acquired via restricted stock vesting from the issuer on 02/02/2024 (361 shares) and 03/27/2024 (4,912 shares), as compensation. The notice also lists a prior sale of 5,745 shares of common stock on 11/11/2025 for gross proceeds of $1,509,498.75.
Labcorp Holdings Inc. director John H. Sampson filed an initial ownership report on Form 3. The filing states that no securities of Labcorp Holdings Inc. are beneficially owned. The report is filed as a single reporting person in the capacity of director.
Labcorp Holdings Inc. (LH) Chief Financial Officer and EVP Julia Aijun Wang reported equity compensation activity on February 6, 2026. 893 Restricted Stock Units vested and converted into 893 shares of common stock, consistent with a multi-year vesting schedule that began on February 6, 2025.
To cover tax withholding obligations, 254 of these shares were withheld at a price of $277.2 per share, leaving 1,202.239 shares of common stock beneficially owned directly after the transactions. Wang also directly holds 3,474 Restricted Stock Units, each representing the right to receive one share of Labcorp common stock.
Labcorp Holdings Inc. executive Brian J. Caveney, EVP, President of Enterprise Diagnostics, CMO and CSO, reported multiple equity transactions tied to vested restricted stock units. On February 6 and 7, 2026, a total of 670, 517 and 111 restricted stock units converted into the same number of Labcorp common shares at an exercise price of
Labcorp Holdings Inc. executive Akinbolade Oyegunwa, EVP, CIO & CTO, reported routine equity compensation activity. On February 6 and 7, 2026, restricted stock units (RSUs) covering 180 and 149 shares of common stock, respectively, were converted into Labcorp common shares.
To cover tax withholding obligations, a total of 112 common shares were withheld, at prices of $277.2 and $274.01 per share. Following these transactions, Oyegunwa directly held 3,944.253 shares of common stock and 1,610 RSUs, each RSU representing the right to receive one share of common stock as they vest over the disclosed schedules.
Labcorp Holdings Inc. President & CEO Adam H. Schechter reported multiple equity transactions. On February 6 and 7, 2026, he exercised restricted stock units, converting 4,460 and 3,249 RSUs into an equal number of common shares at an exercise price of $0 per share. Related grants vest in three equal annual installments beginning on February 6, 2025 and February 7, 2024.
To cover tax withholding, Schechter had 1,315 shares withheld at $277.20 on February 6, 2026 and 1,352 shares withheld at $274.01 on February 9, 2026. After these transactions, he directly held 92,616 shares of common stock and 18,679 restricted stock units.
Labcorp Holdings Inc. executive Peter J. Wilkinson, SVP and Chief Accounting Officer, reported multiple equity award transactions. On February 6 and 7, 2026, Restricted Stock Units (RSUs) vested and were converted into 133 and 134 shares of common stock, respectively, each RSU representing one share.
To cover tax withholding obligations related to these vestings, 45 shares at $277.20 per share on February 6 and 46 shares at $274.01 per share on February 9 were withheld. After these transactions, Wilkinson directly held 2,028.2194 shares of Labcorp common stock and 2,224 RSUs in total.
Labcorp Holdings Inc. executive Mark S. Schroeder, EVP, President Diagnostics & COO, reported multiple equity compensation events in early February 2026. On February 6–7, 2026, a total of 1,424 Restricted Stock Units converted into an equal number of common shares at a stated price of
To cover tax withholding obligations, the company withheld 239 common shares at